Scientists have identified a molecular marker called “Mig 6” that appears to accurately predict longer survival — up to two years — among patients prescribed two of the most widely used drugs in a class of anticancer agents called EGFR inhibitors.
Scientists have identified a molecular marker called “Mig 6” that appears to accurately predict longer survival — up to two years — among patients prescribed two of the most widely used drugs in a class of anticancer agents called EGFR inhibitors.